Dyadic International (NASDAQ:DYAI) Stock Passes Below Fifty Day Moving Average – Here’s What Happened

Dyadic International, Inc. (NASDAQ:DYAI) crossed below its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of $1.13 and traded as low as $1.05. Dyadic International shares last traded at $1.14, with a volume of 32,764 shares changing hands.

Dyadic International Stock Up 8.6 %

The firm has a market capitalization of $33.61 million, a P/E ratio of -4.07 and a beta of 0.72. The firm’s 50 day moving average is $1.13 and its two-hundred day moving average is $1.42. The company has a debt-to-equity ratio of 1.72, a current ratio of 5.39 and a quick ratio of 5.39.

Dyadic International (NASDAQ:DYAI) last released its quarterly earnings data on Tuesday, August 13th. The biotechnology company reported ($0.07) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.01). Dyadic International had a negative return on equity of 145.95% and a negative net margin of 428.86%. The firm had revenue of $0.39 million for the quarter, compared to analyst estimates of $1.00 million. During the same quarter in the prior year, the firm earned ($0.07) earnings per share. Research analysts predict that Dyadic International, Inc. will post -0.28 EPS for the current year.

Institutional Trading of Dyadic International

An institutional investor recently raised its position in Dyadic International stock. Chapin Davis Inc. boosted its stake in shares of Dyadic International, Inc. (NASDAQ:DYAI) by 2.5% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 847,301 shares of the biotechnology company’s stock after purchasing an additional 21,000 shares during the quarter. Chapin Davis Inc. owned about 2.90% of Dyadic International worth $1,254,000 at the end of the most recent reporting period. Institutional investors own 27.95% of the company’s stock.

About Dyadic International

Dyadic International, Inc, a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health.